These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 19843504)

  • 1. Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.
    Hudon V; Sabourin S; Dydensborg AB; Kottis V; Ghazi A; Paquet M; Crosby K; Pomerleau V; Uetani N; Pause A
    J Med Genet; 2010 Mar; 47(3):182-9. PubMed ID: 19843504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).
    Lu X; Boora U; Seabra L; Rabai EM; Fenton J; Reiman A; Nagy Z; Maher ER
    Oncogene; 2014 Feb; 33(8):956-65. PubMed ID: 23416984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.
    Chen J; Futami K; Petillo D; Peng J; Wang P; Knol J; Li Y; Khoo SK; Huang D; Qian CN; Zhao P; Dykema K; Zhang R; Cao B; Yang XJ; Furge K; Williams BO; Teh BT
    PLoS One; 2008; 3(10):e3581. PubMed ID: 18974783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein.
    Takagi Y; Kobayashi T; Shiono M; Wang L; Piao X; Sun G; Zhang D; Abe M; Hagiwara Y; Takahashi K; Hino O
    Oncogene; 2008 Sep; 27(40):5339-47. PubMed ID: 18663353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
    Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.
    Hasumi H; Baba M; Hasumi Y; Furuya M; Yao M
    Int J Urol; 2016 Mar; 23(3):204-10. PubMed ID: 26608100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer.
    Nahorski MS; Lim DH; Martin L; Gille JJ; McKay K; Rehal PK; Ploeger HM; van Steensel M; Tomlinson IP; Latif F; Menko FH; Maher ER
    J Med Genet; 2010 Jun; 47(6):385-90. PubMed ID: 20522427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folliculin deficient renal cancer cells show higher radiosensitivity through autophagic cell death.
    Zhang Q; Si S; Schoen S; Jin XB; Chen J; Wu G
    J Urol; 2014 Jun; 191(6):1880-8. PubMed ID: 24434776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?
    Johannesma PC; Houweling AC; Menko FH; van de Beek I; Reinhard R; Gille JJ; van Waesberghe JT; Thunnissen E; Starink TM; Postmus PE; van Moorselaar RJ
    Fam Cancer; 2016 Apr; 15(2):297-300. PubMed ID: 26603437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.
    Lu X; Wei W; Fenton J; Nahorski MS; Rabai E; Reiman A; Seabra L; Nagy Z; Latif F; Maher ER
    Mol Cancer Ther; 2011 Jan; 10(1):80-9. PubMed ID: 21220493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.
    Näf E; Laubscher D; Hopfer H; Streit M; Matyas G
    Fam Cancer; 2016 Jan; 15(1):127-32. PubMed ID: 26342594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterozygous germline FLCN mutation in Birt-Hogg-Dubé syndrome with bilateral renal hybrid oncocytic/chromophobe tumor and unilateral renal chromophobe cell carcinoma: a case report.
    Li J; Liu F; Liu X; Hu Y; Liu Z; Shen Y; Wan J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2319-2325. PubMed ID: 36258004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of tubular Flcn expression as a mouse model for renal tumor induction.
    Chen J; Huang D; Rubera I; Futami K; Wang P; Zickert P; Khoo SK; Dykema K; Zhao P; Petillo D; Cao B; Zhang Z; Si S; Schoen SR; Yang XJ; Zhou M; Xiao GQ; Wu G; Nordenskjöld M; Tauc M; Williams BO; Furge KA; Teh BT
    Kidney Int; 2015 Nov; 88(5):1057-69. PubMed ID: 26083655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancer.
    Bartram MP; Mishra T; Reintjes N; Fabretti F; Gharbi H; Adam AC; Göbel H; Franke M; Schermer B; Haneder S; Benzing T; Beck BB; Müller RU
    BMC Med Genet; 2017 May; 18(1):53. PubMed ID: 28499369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation.
    Hasumi H; Hasumi Y; Baba M; Nishi H; Furuya M; Vocke CD; Lang M; Irie N; Esumi C; Merino MJ; Kawahara T; Isono Y; Makiyama K; Warner AC; Haines DC; Wei MH; Zbar B; Hagenau H; Feigenbaum L; Kondo K; Nakaigawa N; Yao M; Metwalli AR; Marston Linehan W; Schmidt LS
    Hum Mol Genet; 2017 Jan; 26(2):354-366. PubMed ID: 28007907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin.
    Tee AR; Pause A
    Fam Cancer; 2013 Sep; 12(3):367-72. PubMed ID: 23096221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Birt-Hogg-Dubé (BHD) syndrome: report of two novel germline mutations in the folliculin (FLCN) gene.
    Palmirotta R; Donati P; Savonarola A; Cota C; Ferroni P; Guadagni F
    Eur J Dermatol; 2008; 18(4):382-6. PubMed ID: 18573707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birt-Hogg-Dubé syndrome.
    Furuya M; Hasumi H; Baba M; Tanaka R; Iribe Y; Onishi T; Nagashima Y; Nakatani Y; Isono Y; Yao M
    Lab Invest; 2017 Mar; 97(3):343-351. PubMed ID: 27991910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.
    Hong SB; Oh H; Valera VA; Stull J; Ngo DT; Baba M; Merino MJ; Linehan WM; Schmidt LS
    Mol Cancer; 2010 Jun; 9():160. PubMed ID: 20573232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of Birt-Hogg-Dubé syndrome implying reduced or no wild-type folliculin without mutated protein is pathogenic.
    Enomoto Y; Namba Y; Hoshika Y; Komemushi Y; Mitani K; Kume H; Kobayashi E; Miyama Y; Homma Y; Ushiku T; Seyama K
    Eur J Med Genet; 2020 Apr; 63(4):103820. PubMed ID: 31778855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.